Verisante Technology, Inc. Welcomes Dr. Kenneth Beer and Dr. Philip Werschler onto Clinical Advisory Board

VANCOUVER, BRITISH COLUMBIA--(Marketwired - Jul 29, 2014) - Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF) (the "Company" or "Verisante"), a leader in cancer detection technology, is pleased to welcome Dr. Kenneth Beer, MD, PA and Dr. Wm. Philip Werschler, MD, FAAD, FAACS, onto the Company's Clinical Advisory Board. "Both Dr. Beer and Dr. Werschler have extensive experience assisting companies with setting up scientific advisory boards, advising with clinical studies and navigating the medical device regulatory regime in the United States," said Thomas Braun, President & CEO. "We are fortunate to have two experts in their field join our Advisory Board and look forward to...